Why Are Cancer Cells Able to Thrive in Conditions That Other Cells Cannot?

Key Takeaways

• Soley uses cell-sensing platform to screen stress‑inducing drugs
• Platform decodes cellular signals to determine fate under stress
• Technology applies to cancer, antimicrobial, and regenerative therapies
• Developed over 15 years from UCSF stem‑cell research
• Targets tumor microenvironment rather than specific molecular targets

Summary

Soley Therapeutics, founded by clinician‑scientist Yerem Yeghiazarians and a cancer biologist, built a decade‑long, image‑based platform that treats cells as sophisticated sensors of their micro‑environment. The technology decodes how cells decide to live or die under low‑oxygen, nutrient‑poor conditions—an environment shared by heart attacks, strokes, and tumors. By leveraging this insight, Soley can screen compounds that either heighten cellular stress to kill cancer cells or alleviate stress to protect heart and neuronal cells. The platform, rooted in UCSF research, is now positioned to accelerate drug discovery across oncology, infectious disease, and regenerative medicine.

Pulse Analysis

The tumor microenvironment—characterized by hypoxia, nutrient scarcity, and acidic pH—has long challenged traditional drug development, which often focuses on single molecular targets. Cells that thrive in such hostile conditions, like cancer cells, reveal adaptive signaling pathways that can be exploited for therapeutic gain. By studying how heart‑muscle and neuronal cells succumb quickly while tumor cells flourish, researchers gain a broader view of cellular resilience, opening avenues beyond conventional oncology paradigms.

Soley Therapeutics translates this biological insight into a proprietary, image‑based platform that treats each cell as a high‑resolution sensor. The system captures real‑time morphological and biochemical cues, then applies machine‑learning algorithms to map stress‑response pathways. This enables rapid, high‑throughput screening of compounds that either amplify stress signals to induce cancer cell death or dampen stress to protect vulnerable tissues. Because the platform evaluates whole‑cell behavior rather than isolated targets, it can uncover multi‑modal drug effects, reduce off‑target toxicity, and accelerate lead identification across therapeutic areas.

For the pharmaceutical industry, Soley’s approach promises a more efficient route to first‑in‑class candidates, especially in oncology and antimicrobial spaces where resistance and tumor heterogeneity are major hurdles. The ability to predict cellular fate under realistic physiological stress could shorten preclinical timelines and improve translational success rates. As investors seek technologies that de‑risk pipelines, Soley’s platform positions itself as a strategic asset for partners aiming to develop next‑generation therapies that address both disease eradication and tissue regeneration.